FMP
Surface Oncology, Inc.
SURF
NASDAQ
Inactive Equity
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
1.07 USD
-0.01 (-0.935%)
Historical Prices
From:
To:
About
ceo
Ms. Lisa McGrath
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement ...
CIK
0001718108
ISIN
US86877M2098
CUSIP
86877M209
Address
50 Hampshire Street
Phone
617 714 4096
Country
US
Employee
35
IPO Date
Apr 19, 2018
Financial Statement
Earnings
SURF Financial Summary
CIK
0001718108
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
86877M209
ISIN
US86877M2098
Country
US
Price
1.07
Beta
1.75
Volume Avg.
798.15k
Market Cap
65.08M
Shares
-
52-Week
0.555-1.43
DCF
2.25
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.69
P/B
-
Website
https://www.surfaceoncology.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SURF News
PennyStocks
Jun 20, 2023
Best Penny Stocks To Buy This Week? 3 To Watch Right Now
This will likely be another active week for traders. Whether you're trading penny stocks or higher priced shares of companies like Tesla (NASDAQ: TSLA) and Apple (NASDAQ: AAPL), chances are you're paying attention to stock market news headlines.
Proactive Investors
Jun 16, 2023
Surface Oncology stock flies on $65M stock-for-stock acquisi...
Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The stock-for-stock transaction is valued at up to $65 million, approximately a three-fold premium over Surface's anticipated net cash of $20 million to $25 million at closing, the two companies said in a statement.
Market Watch
Jun 16, 2023
Surface Oncology stock rallies on all-stock acquisition by C...
Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by Coherus BioSciences Inc. CHRS, +0.56% in a stock-for-stock deal valued at up to $65 million. Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock for a total value equal to the sum of $40 million.
GlobeNewsWire
Nov 7, 2022
Surface Oncology to Present Non-clinical Data for SRF388 and...
Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs
GlobeNewsWire
Sep 14, 2022
Surface Oncology to Present Preclinical Data Highlighting th...
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -
GlobeNewsWire
Sep 7, 2022
Surface Oncology to Participate in the Baird 2022 Global Hea...
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.
GlobeNewsWire
May 26, 2022
Surface Oncology to Present New SRF388 Clinical Data at 2022...
– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –
Seeking Alpha
May 25, 2022
Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able ...
Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either.
